Anebulo Pharmaceuticals (ANEB) Competitors $1.26 -0.16 (-10.95%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.28 +0.02 (+1.59%) As of 02/21/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ANEB vs. CHRS, BMEA, BDTX, CABA, TSVT, KYTX, SGMT, IVA, RENB, and TELOShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Coherus BioSciences (CHRS), Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), 2seventy bio (TSVT), Kyverna Therapeutics (KYTX), Sagimet Biosciences (SGMT), Inventiva (IVA), Renovaro (RENB), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Coherus BioSciences Biomea Fusion Black Diamond Therapeutics Cabaletta Bio 2seventy bio Kyverna Therapeutics Sagimet Biosciences Inventiva Renovaro Telomir Pharmaceuticals Anebulo Pharmaceuticals (NASDAQ:ANEB) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability. Do institutionals & insiders hold more shares of ANEB or CHRS? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend ANEB or CHRS? Anebulo Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 534.92%. Coherus BioSciences has a consensus target price of $5.38, suggesting a potential upside of 402.34%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Anebulo Pharmaceuticals is more favorable than Coherus BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community favor ANEB or CHRS? Coherus BioSciences received 439 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.00% of users gave Anebulo Pharmaceuticals an outperform vote while only 65.31% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformAnebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00%Coherus BioSciencesOutperform Votes44865.31% Underperform Votes23834.69% Which has more risk & volatility, ANEB or CHRS? Anebulo Pharmaceuticals has a beta of -1.15, meaning that its stock price is 215% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Which has better valuation & earnings, ANEB or CHRS? Anebulo Pharmaceuticals has higher earnings, but lower revenue than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.28-4.50Coherus BioSciences$257.24M0.48-$237.89M-$0.08-13.38 Does the media refer more to ANEB or CHRS? In the previous week, Anebulo Pharmaceuticals had 1 more articles in the media than Coherus BioSciences. MarketBeat recorded 1 mentions for Anebulo Pharmaceuticals and 0 mentions for Coherus BioSciences. Anebulo Pharmaceuticals' average media sentiment score of 0.42 beat Coherus BioSciences' score of 0.00 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Anebulo Pharmaceuticals Neutral Coherus BioSciences Neutral Is ANEB or CHRS more profitable? Anebulo Pharmaceuticals has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -119.54% -108.08% Coherus BioSciences -0.15%N/A -24.44% SummaryAnebulo Pharmaceuticals beats Coherus BioSciences on 9 of the 17 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.70M$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-4.506.1326.4618.82Price / SalesN/A311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book2.176.747.634.64Net Income-$8.20M$138.11M$3.18B$245.69M7 Day Performance-5.26%-2.43%-1.91%-2.66%1 Month Performance-21.25%-1.91%-0.19%-2.15%1 Year Performance-56.55%-5.03%16.70%12.90% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals3.2404 of 5 stars$1.26-11.0%$8.00+534.9%-58.0%$58.13MN/A-4.504Earnings ReportNews CoverageGap UpCHRSCoherus BioSciences3.6681 of 5 stars$1.18+1.7%$5.38+355.5%-56.9%$136.75M$257.24M-14.75330BMEABiomea Fusion3.3375 of 5 stars$3.73+3.3%$39.36+955.3%-77.4%$135.17MN/A-0.9350Positive NewsBDTXBlack Diamond Therapeutics3.3805 of 5 stars$2.37+1.3%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive NewsCABACabaletta Bio2.2422 of 5 stars$2.71+0.4%$22.71+738.2%-90.7%$132.47MN/A-1.2650Analyst ForecastTSVT2seventy bio2.1813 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoverageKYTXKyverna Therapeutics1.1479 of 5 stars$3.03-0.3%$25.71+748.7%-89.9%$130.81M$7.03M0.0096SGMTSagimet Biosciences1.8145 of 5 stars$4.25-3.4%$23.00+441.2%-38.9%$130.35M$2M0.008IVAInventiva2.0097 of 5 stars$2.47-0.4%$13.25+436.4%-13.1%$129.63M$18.91M0.00100Analyst ForecastNews CoverageGap UpRENBRenovaro0.763 of 5 stars$0.81+9.0%N/A-61.1%$128.39MN/A-0.8420Earnings ReportNews CoverageGap UpTELOTelomir Pharmaceuticals2.2818 of 5 stars$4.29+0.5%N/A-54.8%$127.67MN/A-7.401Analyst ForecastNews Coverage Related Companies and Tools Related Companies Coherus BioSciences Alternatives Biomea Fusion Alternatives Black Diamond Therapeutics Alternatives Cabaletta Bio Alternatives 2seventy bio Alternatives Kyverna Therapeutics Alternatives Sagimet Biosciences Alternatives Inventiva Alternatives Renovaro Alternatives Telomir Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANEB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANEB Stock Alerts